CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Smith, Matthew Raymond
Piulats, Josep M.
Todenhofer, Tilman
Lee, Jae-Lyun
Arija, Jose Angel Arranz
Mazilu, Laura
Azad, Arun
Alonso-Gordoa, Teresa
McGovern, Ursula Brigid
Choudhury, Atish Dipankar
Ye, Dingwei
Suzuki, Hiroyoshi
Mckay, Rana R.
Ades, Steven
Flechon, Aude
Pieczonka, Christopher Michael
Hulstijn, Maarten
Lithio, Andrew
Nacerddine, Karim
Agarwal, Neeraj
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Inst Catal Oncol Bellvitge Inst Biomed Res, Barcelona, Spain
[3] Studienpraxis Urol, Nurtingen, Germany
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Hosp Univ Gregorio Maranon, Madrid, Spain
[6] Clin Emergency Hosp, Constanta, Romania
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[8] Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid, Spain
[9] Univ Coll Hosp London, London, England
[10] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[11] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[12] Toho Univ, Sakura Med Ctr, Chiba, Japan
[13] Univ Calif San Diego, La Jolla, CA USA
[14] Univ Vermont, Larner Coll Med, Burlington, VT USA
[15] Ctr Leon Berard, Lyon, France
[16] Associated Med Professionals NY, Syracuse, NY USA
[17] Eli Lilly & Co, Indianapolis, IN USA
[18] Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5001
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [32] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
    McKay, Rana R.
    Werner, Lillian
    Jacobus, Susanna J.
    Jones, Xandra
    Mostaghel, Elahe A.
    Marck, Brett T.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Sweeney, Christopher J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2019, 125 (04) : 524 - 532
  • [33] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [34] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
    Onal, Cem
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildirim, Berna Akkus
    Besen, Ali Ayberk
    Muallaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    FUTURE ONCOLOGY, 2019, 15 (13) : 1469 - 1479
  • [35] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer
    Sheridan M. Hoy
    Drugs, 2013, 73 : 2077 - 2091
  • [37] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [38] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [39] Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer
    Hoy, Sheridan M.
    DRUGS, 2013, 73 (18) : 2077 - 2091
  • [40] NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY
    Chi, Kim
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, R. Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald
    JOURNAL OF UROLOGY, 2022, 207 (05): : E456 - E457
12345